1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024

Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. The majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in the commercialization of antibacterial drugs as well as new participants who wish to enter the U.S. market.

This market study provides a complete analysis of the bacterial conjunctivitis drugs market in the U.S. and helps in identifying various market governing factors. The market overview section provides exhaustive information of the incidence rate of bacterial conjunctivitis, list of API manufacturers, patent challenges, market trends such as drivers, restraints, and growth opportunities that currently control the dynamics of the overall market. The section also recommends and predicts the future conditions of the market. Market strategy tools such as event impact assessment and Porter’s Five Forces analysis have also been incorporated in this report to provide balanced analysis about the level of competition within the bacterial conjunctivitis drugs market in the U.S. Executive summary provided in the report encapsulates comprehensive insights about every segment considered in this study. Besides, it includes a market snapshot, which offers a glimpse into the current scenario of the bacterial conjunctivitis drugs market in the U.S. in terms of current and future market size along cumulative growth rate. Additionally, this study includes a regulatory framework segment wherein the overall regulatory scenario of the U.S. drugs policy has been described. Participant analysis tools such as market share analysis have also been included in the market overview section of the report to deliver a broad spectrum of the overall market scenario in the bacterial conjunctivitis drugs market in the U.S.

The bacterial conjunctivitis drugs market in the U.S. has been segmented based on various antibacterial drug classes. The market is segmented into major types of antibacterial drugs such as fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones segment has been sub-segmented into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin. Aminoglycosides have been sub-segmented into tobramycin and gentamycin. Macrolides has been divided into erythromycin and azithromycin. The others segment is analyzed cumulatively, considering bacitracin, fusidic acid, and ceftriaxone within this class. The market size for the period from 2012 to 2024 has been provided for each of the major drug classes mentioned above in terms of USD million. Along with the market size that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2012 to 2018 and 2018 to 2024 have also been provided.

The report concludes with detailed profiles of leading players in the bacterial conjunctivitis drugs (antibacterials) market in the U.S. The study profiles the companies in terms of overview, financial overview, product portfolio, business strategies, and recent developments. Major organizations profiled in this report include Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. Additionally, market share analysis that has been provided in context with the major pharmaceuticals operating in the market would help new participants to understand the key business perceptions and frameworks and to identify the specific product lines of the existing companies to establish a strong foothold in the bacterial conjunctivitis drugs market in the U.S.

The U.S. bacterial conjunctivitis drugs market is segmented as follows:

U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
Fluoroquinolones
Ciprofloxacin
Ofloxacin
Levofloxacin
Moxifloxacin
Gatifloxacin
Besifloxacin
Aminoglycosides
Tobramycin
Gentamycin
Macrolides
Erythromycin
Azithromycin
Others
U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
Vancomycin Ophthalmic Ointment
Early Stage (Phase I and Phase II trials) – Tabular Representation

Table Of Contents

The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024
Chapter 1 Preface

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 Assumptions

Chapter 2 Executive Summary

2.1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview

3.1 Market Dynamics and Overview

3.2 Incidence Rate of Bacterial Conjunctivitis in the U.S.

3.3 Market Drivers

3.3.1 Rising Incidence of Ophthalmic Bacterial Infection

3.3.2 Susceptibility Among Various Age Groups Ranging from Neonates to Geriatrics

3.4 Market Restraints

3.4.1 Increasing Genericization of Antibacterial Drugs Could Lead to a Crowded and Unprofitable Market

3.4.2 Upcoming Patent Expirations likely to Hinder Market Growth

3.4.3 Burgeoning Multi-Drug Resistant Bacterial Strains Expected To Hinder Market Growth

3.5 Market Opportunities

3.5.1 Implementation of Product Development Partnerships (PDPs) Business Models

3.5.2 Focus on Designing and Producing Combination Drug Products

3.6 Event Impact Assessment: U.S. Bacterial Conjunctivitis Market

3.7 Regulatory Framework

3.8 Patents and Patent Challenges: Overview

3.9 List of API Manufacturers

3.10 Key Discontinued Products: U.S. Bacterial Conjunctivitis Drugs Market

3.10.1 Oxytetracycline/Polymyxin B

3.10.2 Sulfisoxazole Ophthalmic

3.10.3 Phenylephrine/Sulfacetamide Sodium

3.10.4 Chloramphenicol

3.11 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Type

3.12 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

4.1 Overview

4.1.1 Recommended Dosages for Treatment of Bacterial Conjunctivitis

4.1.2 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 - 2024 (USD Million)

4.2 Fluoroquinolones

4.2.1 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2024 (USD Million)

4.2.2 Ciprofloxacin

4.2.2.1 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.2.3 Ofloxacin

4.2.3.1 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.2.4 Levofloxacin

4.2.4.1 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.2.5 Moxifloxacin

4.2.5.1 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.2.6 Gatifloxacin

4.2.6.1 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.2.7 Besifloxacin

4.2.7.1 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.3 Aminoglycosides

4.3.1 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2024 (USD Million)

4.3.2 Tobramycin

4.3.2.1 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.3.3 Gentamycin

4.3.3.1 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.4 Macrolides

4.4.1 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2024 (USD Million)

4.4.2 Erythromycin

4.4.2.1 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.4.3 Azithromycin

4.4.3.1 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

4.5 Others (Bacitracin, Doxycycline, Polymyxin, and Fusidic Acid)

4.5.1.1 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 - 2024 (USD Million)

Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment

5.1 Overview

5.2 Vancomycin Ophthalmic Ointment

5.2.1 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 - 2024 (USD Million)

5.3 Early Stage (Phase I and Phase II trials) - Tabular Representation

Chapter 6 Recommendations

Chapter 7 Company Profiles

7.1 Actavis plc (now Allergan plc)

7.1.1 Company Overview

7.1.2 Financial Overview

7.1.3 Product Portfolio

7.1.4 Business Strategies

7.1.5 Recent Developments

7.2 Akorn, Inc.

7.2.1 Company Overview

7.2.2 Financial Overview

7.2.3 Product Portfolio

7.2.4 Business Strategies

7.2.5 Recent Developments

7.3 Bayer AG

7.3.1 Company Overview

7.3.2 Financial Overview

7.3.3 Product Portfolio

7.3.4 Business Strategies

7.3.5 Recent Developments

7.4 F. Hoffmann-La Roche Ltd.

7.4.1 Company Overview

7.4.2 Financial Overview

7.4.3 Product Portfolio

7.4.4 Business Strategies

7.4.5 Recent Developments

7.5 Merck and Co., Inc.

7.5.1 Company Overview

7.5.2 Financial Overview

7.5.3 Product Portfolio

7.5.4 Business Strategies

7.5.5 Recent Developments

7.6 Novartis AG

7.6.1 Company Overview

7.6.2 Financial Overview

7.6.3 Product Portfolio

7.6.4 Business Strategies

7.6.5 Recent Developments

7.7 Perrigo Company plc

7.7.1 Company Overview

7.7.2 Financial Overview

7.7.3 Product Portfolio

7.7.4 Business Strategies

7.7.5 Recent Developments

7.8 Pfizer, Inc.

7.8.1 Company Overview

7.8.2 Financial Overview

7.8.3 Product Portfolio

7.8.4 Business Strategies

7.8.5 Recent Developments

7.9 Santen Pharmaceutical Co., Ltd.

7.9.1 Company Overview

7.9.2 Financial Overview

7.9.3 Product Portfolio

7.9.4 Business Strategies

7.9.5 Recent Developments

7.10 Valeant Pharmaceuticals International, Inc.

7.10.1 Company Overview

7.10.2 Financial Overview

7.10.3 Product Portfolio

7.10.4 Business Strategies

7.10.5 Recent Developments

List of Tables

TABLE 1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

TABLE 2 Upcoming Patents Expiration of Branded Bacterial Conjunctivitis Drugs and Competing Companies of Generic Products

TABLE 3 List of Ciprofloxacin API Manufacturers

TABLE 4 List of Ofloxacin API Manufacturers

TABLE 5 List of Levofloxacin API Manufacturers

TABLE 6 List of Moxifloxacin API Manufacturers

TABLE 7 List of Gatifloxacin API Manufacturers

TABLE 8 List of Besifloxacin API Manufacturers

TABLE 9 List of Tobramycin API Manufacturers

TABLE 10 List of Gentamycin API Manufacturers

TABLE 11 List of Erythromycin API Manufacturers

TABLE 12 List of Azithromycin API Manufacturers

TABLE 13 List of Bacitracin API Manufacturers

TABLE 14 List of Neomycin API Manufacturers

TABLE 15 List of Fusidic Acid API Manufacturers

TABLE 16 Recommended Dosages for Treatment of Bacterial Conjunctivitis

TABLE 17 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 - 2018 (USD Million)

TABLE 18 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2019 - 2024 (USD Million)

TABLE 19 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2018 (USD Million)

TABLE 20 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 - 2024 (USD Million)

TABLE 21 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2018 (USD Million)

TABLE 22 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 - 2024 (USD Million)

TABLE 23 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 - 2018 (USD Million)

TABLE 24 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 - 2024 (USD Million)

TABLE 25 Early Stage (Phase I and Phase II trials) - Tabular Representation

TABLE 26 Actavis plc: Expenses and Revenue, 2011 - 2013 (USD Million)

TABLE 27 Novartis AG: Expenses and Revenue, 2011 - 2013 (USD Million)

List of Figures

FIG. 1 U.S. Bacterial Conjunctivitis Drugs Market Segmentation

FIG. 1 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class, 2013 (USD Million)

FIG. 2 U.S. Bacterial Conjunctivitis Drugs Market: Drivers, and Restraints

FIG. 3 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

FIG. 4 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

FIG. 5 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 6 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 7 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 8 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 9 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 10 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 11 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 12 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 13 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 14 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 - 2024 (USD Million)

FIG. 15 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 - 2024 (USD Million)

FIG. 16 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 - 2024 (USD Million)

FIG. 17 Actavis plc.: Annual Revenue, 2011 - 2013 (USD Million)

FIG. 18 Akorn, Inc.: Annual Revenue, 2011 - 2013 (USD million)

FIG. 19 Bayer AG (Bayer HealthCare): Annual Revenue, 2011 - 2013 (USD Million)

FIG. 20 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 - 2013 (USD Million)

FIG. 21 Annual Revenue: Merck and Co., Inc., 2011 - 2013 (USD Million)

FIG. 22 Novartis AG: Annual Revenue, 2011 - 2013 (USD Million)

FIG. 23 Perrigo Company plc.: Annual Revenue, 2011 - 2013 (USD Million)

FIG. 24 Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

FIG. 25 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2011 - 2013 (USD million)

FIG. 26 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Ghana

  • December 2016
    10 pages
  • Anti-Infective  

  • Ghana  

View report >

Anti-Infective and Therapy Market in the US - Forecast

  • December 2016
    249 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Anti-Infective Market in Canada

  • November 2016
    215 pages
  • Anti-Infective  

    Civil Protectio...  

    Environment  

  • Canada  

    North America  

View report >

Related Market Segments :

Anti-Infective
Eye Disease

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.